Press releases
Genoskin brings unique alternative to animal testing to the US
Genoskin finalist of Start-Up Connexion 2017
On February 3, 2017, Genoskin was awarded a finalist spot in the third edition of the Start-up Connexion Contest. This event brings together innovative research companies and potential investors to highlight and finance projects with high economic value. The Start-up Connexion Contest is a combined initiative of the CNRS (French National Center for Scientific Research) and the AEF Media Group, which specializes in
ISO9001 certification
Genoskin obtains ISO9001 certification The entire Genoskin team is proud to announce that we obtained the ISO9001:2015 certification in January 2017. This certificate validates the quality and consistency of our design and R&D services as well as the commercialization of human skin models, cells and tissues to pharmaceutical, chemical and cosmetic industries. Consistent quality for skin models and R&D programs The
Genoskin is a winner of the 7th edition of the NETVA contest: See you soon in Boston !
The NETVA (New Technology Venture Accelerator) program consists in a preparation and exposure to high-tech US markets for young innovative French companies. It is run by the Office for Science & Technology of the Embassy of France in the United States in three locations: Boston, San Francisco and Washington, DC. Each year, 15 French startups are selected though a national competition
Australian University uses NativeSkin® models to study UVB skin damage
NativeSkin® successfully treated with UVB after shipment from France to Australia May 2016. Dr. Ziman’s lab. (Edith Cowan University, Perth, Western Australia) reports the successful use of NativeSkin models, shipped from France to Australia, to study skin damages induced by UVB and heat. Researchers analyzed the consequences of UVB and/or heat treatments by co-immunofluorescence staining perform on NativeSkin skin models-fixed tissue, as shown in the
Genoskin presents new skin cancer model at Meet2Win
Genoskin launches new OncoSkin® skin cancer model at Meet2Win Genoskin has developed a new skin cancer model for the in vitro study of melanoma. Patients who suffer from this highly dangerous type of skin cancer currently have limited therapeutic options when the cancer reaches metastasis. The OncoSkin® skin cancer model now enables in vitro studies on live melanoma spheroids implanted
Genoskin develops and markets innovative testing tools to study the effects of pharmaceutical, cosmetic and chemical products on real, live ex vivo human skin.
